CD274 and neoplasm: The levels of neoantigens and PD-L1 expression serve as foundational criteria for administering immunotherapy to TNBC patients.[14,160] The expression status of PD-L1, the abundance of TILs, and the tumor mutational burden (TMB) are three pivotal factors influencing the response to ICI.